gemcitabine has been researched along with Adenocarcinoma, Clear Cell in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, T; Kiyokawa, T; Kohno, T; Kuroda, T; Ogiwara, H; Okamoto, A; Sasaki, M; Sudo, K; Takahashi, K; Tamura, K; Yoshida, H | 1 |
| Kohno, T; Kuroda, T | 1 |
| Berjon, A; Brenes, J; Casado, G; Castelo, B; Espinosa, E; Feliu, J; Gallego, A; Hardisson, D; Hernandez, A; Mendiola, M; Ramon-Patino, J; Redondo, A | 1 |
| Lam, LL; Levingston, R; O'Neill, RS; Solanki, P; Thomas, D | 1 |
| Anjarwalla, S; Lakshmaiah, S; Marzouk, O | 1 |
| Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
| Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 1 |
| Adrover Cebrian, E; Alonso Carrion, L; Arcusa Lanza, A; Bover Barcelo, I; Calvo Garcia, E; Casado Herraez, A; Churruca Galaz, C; Fabregat i Mayol, X; Gonzalez Martin, A; Herrero Ibañez, A; Mellado, B; Ojeda Gonzalez, B; Poveda Velasco, A; Rubio Perez, MJ | 1 |
| Berros, JP; Blay, P; Crespo, G; Esteban, E; Fernández, Y; Fonseca, PJ; Fra, J; Lacave, AJ; Losa, R; Luque, M; Muriel, C; Sanmamed, M; Sierra, M; Villanueva, N | 1 |
| Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A | 1 |
| Aoki, D; Bartholomeusz, C; Ishihara, H; Itamochi, H; Kigawa, J; Suzuki, N; Terakawa, N; Ueno, NT; Walker, CL; Yoshida, T | 1 |
| Dudek, AZ; Liu, SV; Ramanathan, RK; Truskinovsky, AM | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Cheewakriangkrai, C; Manopunya, M; Suprasert, P | 1 |
| Adaniel, C; Aghajanian, C; Grisham, RN; Hyman, DM; Iasonos, A; Konner, J; Ma, W | 1 |
| Danova, M; Imarisio, I; Natalizi, A; Porta, C; Riccardi, A; Sartore-Bianchi, A; Zimatore, M | 1 |
| Arias de la Vega, F; Gómez Dorronsoro, ML; Jiménez, FJ | 1 |
| Boaz, M; Brenner, J; Golan, A; Grisaru, D; Hayat, H; Inbar, M; Levy, T; Menczer, J; Ron, I; Safra, T | 1 |
| Komiyama, S; Kurahashi, T; Kuwabara, Y; Mikami, M; Murakami, I; Nakamura, M; Tanaka, K | 1 |
1 review(s) available for gemcitabine and Adenocarcinoma, Clear Cell
| Article | Year |
|---|---|
Precision medicine for ovarian clear cell carcinoma based on gene alterations.
Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Dosage; Glutathione; Humans; Molecular Targeted Therapy; Mutation; Ovarian Neoplasms; Precision Medicine; Transcription Factors | 2020 |
4 trial(s) available for gemcitabine and Adenocarcinoma, Clear Cell
| Article | Year |
|---|---|
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2013 |
A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Ribonucleotide Reductases; Survival Rate | 2008 |
Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Polyethylene Glycols; Survival Rate; Tissue Distribution; Treatment Outcome | 2011 |
Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Carcinoma, Renal Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunotherapy; Kidney Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Sarcoma; Survival Rate; Therapeutics; Treatment Outcome | 2004 |
14 other study(ies) available for gemcitabine and Adenocarcinoma, Clear Cell
| Article | Year |
|---|---|
Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Gene Knockout Techniques; HCT116 Cells; HEK293 Cells; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Middle Aged; Nuclear Proteins; Ovarian Neoplasms; Random Allocation; Transcription Factors; Xenograft Model Antitumor Assays | 2019 |
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Confidence Intervals; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2021 |
Clear cell adenocarcinoma presenting as acute pancreatitis: A rare form of primary pancreatic malignancy.
Topics: Adenocarcinoma, Clear Cell; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreas; Pancreatic Neoplasms; Pancreatitis; Tomography, X-Ray Computed | 2020 |
Perihilar clear cell cholangiocarcinoma: an often-diagnostic challenge.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biopsy; Cholangiography; Cholangiopancreatography, Magnetic Resonance; Cisplatin; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Fatal Outcome; Gemcitabine; Hepatic Duct, Common; Humans; Klatskin Tumor; Male; Palliative Care; Positron Emission Tomography Computed Tomography | 2020 |
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome | 2011 |
Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27.
Topics: Adenocarcinoma, Clear Cell; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Deoxycytidine; Doxorubicin; Enzyme Activation; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation | 2011 |
Metastatic clear cell adenocarcinoma of the urethra in a male patient: report of a case.
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Treatment Outcome; Urethral Neoplasms | 2012 |
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2013 |
Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antimetabolites, Antineoplastic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2012 |
Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.
Topics: Adenocarcinoma, Clear Cell; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-125 Antigen; Cystadenocarcinoma, Serous; Deoxycytidine; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2012 |
Subcutaneous metastasis as the first manifestation of a solid-pseudopapillary tumor of the pancreas.
Topics: Adenocarcinoma, Clear Cell; Aged; Antimetabolites, Antineoplastic; Arm; Biomarkers; Biomarkers, Tumor; Deoxycytidine; Diagnostic Errors; Female; Gemcitabine; Humans; Keratins; Neoplasm Proteins; Neprilysin; Neuroendocrine Tumors; Pancreatic Neoplasms; Phosphopyruvate Hydratase; Soft Tissue Neoplasms; Subcutaneous Tissue; Vimentin | 2006 |
Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Salvage Therapy; Survival Rate | 2006 |
A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine.
Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritonitis; Salvage Therapy | 2008 |